Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy.
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2013
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 20 Oct 2011 Actual end date (December 2010) added as reported by ClinicalTrials.gov.
- 20 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.